Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations
This article was originally published in RPM Report
Executive Summary
Genentech appears to be having significant manufacturing problems for some of its new cancer therapies. FDA hasn’t taken enforcement action yet, but the agency has delayed two approvals and tied them to post-market requirements to address QC issues.